Analysts at Raymond James, Canaccord and BTIG raised their price targets for Ceribell following the company’s second-quarter fiscal 2026 results and updated growth outlook.
Raymond James increased its price target to $29 from $24, maintaining a Strong Buy rating and introducing 2028 estimates. Canaccord raised its target to $26 from $25 with a Buy rating, while BTIG lifted its target to $30 from $28. Ceribell’s shares traded at $24.81, near a 52-week high, as the stock has gained 114% over the past year and 13% year-to-date in 2025.
The company reported Q2 FY2026 revenue of $28.1 million, a 33% year-over-year increase that accelerated from 29% growth in the prior quarter. Gross margins stood at 89%, according to InvestingPro data. However, Ceribell posted a loss per share of $0.51, wider than the $0.36 loss anticipated by analysts. The firm added 32 new accounts during the quarter, slightly below Canaccord’s estimate of 36.
Raymond James highlighted new growth vectors in neonatology, pediatric care and delirium monitoring. The analyst cited Ceribell’s expanding product portfolio, including a headband, full assembly and recorder, as key drivers. BTIG noted the company’s leadership in point-of-care rapid EEG technology and its recent FDA approval for expanded use in pediatric and neonatal applications.
